What is Sonnest?
Sonnest, Inc. is a specialized pre-clinical healthcare enterprise focused on the development of Electrast, a novel voltage-activated ultrasound imaging agent. The technology functions by circulating through the body in an inactive, dark state on ultrasound, only becoming activated upon reaching the myocardium. This mechanism allows clinicians to evaluate heart perfusion with unprecedented precision at the point of care. By eliminating the need for ionizing radiation or toxic contrast dyes, Sonnest is addressing a critical gap in diagnostic cardiology, offering a cost-effective and safer alternative for real-time myocardial assessment.
How much funding has Sonnest raised?
Sonnest has raised a total of $4M across 1 funding round:
Series A
$4M
Series A (2021): $4M with participation from SWAN Impact Network, Texas Halo Fund, and Robin Hood Ventures
Key Investors in Sonnest
Texas Halo Fund
Texas HALO Fund, LLC is an investment company specializing in early-stage investments in businesses with promising growth prospects and exceptional management teams.
Robin Hood Ventures
Robin Hood Ventures is a leading angel investment group based in Philadelphia, specializing in early-stage, high-growth startups across sectors including Life Sciences.
SWAN Impact Network
An impact-focused investment network dedicated to supporting innovative ventures that generate both financial returns and positive societal outcomes.
What's next for Sonnest?
With the recent capital deployment, Sonnest is expected to prioritize the optimization of its Electrast platform and the expansion of its pre-clinical data sets. The strategic focus will likely shift toward establishing robust safety profiles and refining the activation kinetics of the drug to ensure seamless integration into existing ultrasound workflows. As the firm moves toward potential clinical trials, the management team will likely leverage its network of institutional backers to navigate the complex regulatory environment associated with diagnostic imaging agents. The company's ability to demonstrate superior diagnostic accuracy compared to traditional methods will be the primary driver of its long-term valuation and market adoption.
See full Sonnest company page
